Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer / inotropic agent presented as an intravenous solution for intravenous use. It is employed to improve cardiac output in acute decompensated heart failure and may be considered in cardiogenic shock under specialist supervision.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, with validated quality systems and regulatory approvals across the European Union. Our distribution network ensures timely delivery and compliance with local import requirements.

Levosimendan is indicated for conditions where enhanced myocardial contractility and vasodilation are required to support cardiac output.

- Acute decompensated heart failure: improves cardiac output, reduces pulmonary capillary wedge pressure, and alleviates dyspnea and peripheral edema in patients with sudden worsening of heart function. - Cardiogenic shock (off‑label): provides inotropic support and vasodilation, helping to restore systemic perfusion and blood pressure when conventional catecholamine therapies are insufficient. - Severe low‑output heart failure: enhances myocardial contractility and reduces afterload, supporting organ perfusion in patients with refractory low‑output states.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Hypotension: transient drop in blood pressure, especially during initial infusion. - Headache: mild to moderate headache reported during treatment. - Nausea: occasional nausea or vomiting. - Tachycardia: increase in heart rate observed in some patients.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring vasopressor support. - Ventricular arrhythmias: life‑threatening cardiac rhythm disturbances. - Anaphylactic reaction: rare hypersensitivity with rash, bronchospasm, or shock.

When using Levosimendan, clinicians should observe specific precautions to minimize risk and ensure safe administration.

- Cardiovascular monitoring: continuous blood pressure and ECG monitoring during infusion. - Concomitant vasodilators: avoid simultaneous high‑dose nitrates or phosphodiesterase inhibitors to prevent excessive hypotension. - Electrolyte balance: correct hypokalemia or hypomagnesemia before starting therapy. - Renal or hepatic impairment: adjust dosing or monitor closely in patients with severe organ dysfunction. - Recent myocardial infarction: use with caution in patients who have had an MI within the past 30 days. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension. - Concurrent potent vasodilators (e.g., nitroprusside, high‑dose nitrates): can cause severe hypotension. - Other inotropic agents (e.g., dobutamine, milrinone): may predispose to arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances, enhancing risk of arrhythmias. - Beta‑blockers: may blunt the inotropic response, requiring dose adjustment. - Anticoagulants: additive effect on bleeding risk should be monitored.